Palmar plantar erythrodysesthesia primary prevention: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
 
(2 intermediate revisions by 2 users not shown)
Line 5: Line 5:


==Overview==
==Overview==
Avoiding excessive manual work and walking, wound care to prevent infection, limb elevation, cold compresses, avoiding extreme temperatures, analgesics, creams and emollients are suggested to prevent, delay onset, and/or decrease the severity of PPE.
Avoiding excessive manual work and walking, [[wound]] care to prevent [[infection]], [[limb]] [[elevation]], [[Cold compression therapy|cold compresses]], avoiding extreme [[temperatures]], [[Analgesic|analgesics]], and creams/[[Emollient|emollients]] are suggested to [[Prevention|prevent]], delay onset, and/or decrease the severity of palmar plantar erythrodysesthesia (PPE).


==Primary prevention==
==Primary Prevention==


A number of measures have been suggested to prevent, delay onset and/or decrease the severity of PPE. General measures include:<ref name="pmid2061446">{{cite journal| author=Baack BR, Burgdorf WH| title=Chemotherapy-induced acral erythema. | journal=J Am Acad Dermatol | year= 1991 | volume= 24 | issue= 3 | pages= 457-61 | pmid=2061446 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2061446  }} </ref> <ref name="pmid10071309">{{cite journal| author=Susser WS, Whitaker-Worth DL, Grant-Kels JM| title=Mucocutaneous reactions to chemotherapy. | journal=J Am Acad Dermatol | year= 1999 | volume= 40 | issue= 3 | pages= 367-98; quiz 399-400 | pmid=10071309 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10071309  }} </ref> <ref name="pmid15341880">{{cite journal| author=Lassere Y, Hoff P| title=Management of hand-foot syndrome in patients treated with capecitabine (Xeloda). | journal=Eur J Oncol Nurs | year= 2004 | volume= 8 Suppl 1 | issue=  | pages= S31-40 | pmid=15341880 | doi=10.1016/j.ejon.2004.06.007 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15341880  }} </ref> <ref name="pmid12660565">{{cite journal| author=Gerbrecht BM| title=Current Canadian experience with capecitabine: partnering with patients to optimize therapy. | journal=Cancer Nurs | year= 2003 | volume= 26 | issue= 2 | pages= 161-7 | pmid=12660565 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12660565  }} </ref>
A number of measures have been suggested to [[Prevention|prevent]], delay onset, and/or decrease the severity of PPE. General measures include:<ref name="pmid2061446">{{cite journal| author=Baack BR, Burgdorf WH| title=Chemotherapy-induced acral erythema. | journal=J Am Acad Dermatol | year= 1991 | volume= 24 | issue= 3 | pages= 457-61 | pmid=2061446 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2061446  }} </ref> <ref name="pmid10071309">{{cite journal| author=Susser WS, Whitaker-Worth DL, Grant-Kels JM| title=Mucocutaneous reactions to chemotherapy. | journal=J Am Acad Dermatol | year= 1999 | volume= 40 | issue= 3 | pages= 367-98; quiz 399-400 | pmid=10071309 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10071309  }} </ref> <ref name="pmid15341880">{{cite journal| author=Lassere Y, Hoff P| title=Management of hand-foot syndrome in patients treated with capecitabine (Xeloda). | journal=Eur J Oncol Nurs | year= 2004 | volume= 8 Suppl 1 | issue=  | pages= S31-40 | pmid=15341880 | doi=10.1016/j.ejon.2004.06.007 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15341880  }} </ref> <ref name="pmid12660565">{{cite journal| author=Gerbrecht BM| title=Current Canadian experience with capecitabine: partnering with patients to optimize therapy. | journal=Cancer Nurs | year= 2003 | volume= 26 | issue= 2 | pages= 161-7 | pmid=12660565 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12660565  }} </ref>


* Avoiding excessive manual work and walking, to prevent excessive pressure or friction to the skin
* Avoiding excessive manual work and walking, to [[Prevention|prevent]] excessive pressure or [[friction]] to the [[skin]]
* Wound care to prevent infection
*[[Wound]] care to [[Prevention|prevent]] [[infection]]
* Limb elevation to reduce edema
*[[Limb]] elevation to reduce [[edema]]
* Cold compresses
*[[Cold compression therapy|Cold compresses]]
* Avoiding extreme temperatures
* Avoiding extreme [[temperatures]]
* Analgesics  
*[[Analgesic|Analgesics]]
* Creams and emollients
* Creams and [[Emollient|emollients]]


==References==
==References==

Latest revision as of 19:27, 8 August 2019

Palmar plantar erythrodysesthesia Microchapters

Home

Overview

Historical perspective

Classification

Pathophysiology

Causes

Differentiating Palmar plantar erythrodysesthesia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural history, Complications, and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Palmar plantar erythrodysesthesia primary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Palmar plantar erythrodysesthesia primary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Palmar plantar erythrodysesthesia primary prevention

CDC on Palmar plantar erythrodysesthesia primary prevention

Palmar plantar erythrodysesthesia primary prevention in the news

Blogs on Palmar plantar erythrodysesthesia primary prevention

Directions to Hospitals Treating Palmar plantar erythrodysesthesia

Risk calculators and risk factors for Palmar plantar erythrodysesthesia primary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mandana Chitsazan, M.D. [2]

Overview

Avoiding excessive manual work and walking, wound care to prevent infection, limb elevation, cold compresses, avoiding extreme temperatures, analgesics, and creams/emollients are suggested to prevent, delay onset, and/or decrease the severity of palmar plantar erythrodysesthesia (PPE).

Primary Prevention

A number of measures have been suggested to prevent, delay onset, and/or decrease the severity of PPE. General measures include:[1] [2] [3] [4]

References

  1. Baack BR, Burgdorf WH (1991). "Chemotherapy-induced acral erythema". J Am Acad Dermatol. 24 (3): 457–61. PMID 2061446.
  2. Susser WS, Whitaker-Worth DL, Grant-Kels JM (1999). "Mucocutaneous reactions to chemotherapy". J Am Acad Dermatol. 40 (3): 367–98, quiz 399-400. PMID 10071309.
  3. Lassere Y, Hoff P (2004). "Management of hand-foot syndrome in patients treated with capecitabine (Xeloda)". Eur J Oncol Nurs. 8 Suppl 1: S31–40. doi:10.1016/j.ejon.2004.06.007. PMID 15341880.
  4. Gerbrecht BM (2003). "Current Canadian experience with capecitabine: partnering with patients to optimize therapy". Cancer Nurs. 26 (2): 161–7. PMID 12660565.